MBA III - 2Seventy Bio Principal Officer
| TSVT Stock | USD 3.75 0.14 3.88% |
Executive
MBA III is Principal Officer of 2Seventy Bio
| Age | 52 |
| Address | 60 Binney Street, Cambridge, MA, United States, 02142 |
| Phone | 617 675 7270 |
| Web | https://www.2seventybio.com |
2Seventy Bio Management Efficiency
The company has return on total asset (ROA) of (0.1902) % which means that it has lost $0.1902 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5189) %, meaning that it created substantial loss on money invested by shareholders. 2Seventy Bio's management efficiency ratios could be used to measure how well 2Seventy Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.41 in 2024. Return On Capital Employed is likely to drop to -0.45 in 2024. At this time, 2Seventy Bio's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 574.1 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 2.3 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Joe Tedrick | Kezar Life Sciences | N/A | |
| Jason Fredette | Mersana Therapeutics | N/A | |
| Paul Bullock | Replimune Group | N/A | |
| Matthew Gosling | Protagonist Therapeutics | 53 | |
| Deborah Palestrant | Relay Therapeutics | N/A | |
| JD Esq | Phathom Pharmaceuticals | N/A | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
| Gayle Gironda | Inozyme Pharma | N/A | |
| Marc Damelin | Mersana Therapeutics | N/A | |
| FACP MD | Protagonist Therapeutics | 65 | |
| Stephen Young | Arcus Biosciences | 55 | |
| David Liu | Protagonist Therapeutics | 74 | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Carter King | Protagonist Therapeutics | 53 | |
| Mary CPA | Cullinan Oncology LLC | 60 | |
| Andrea JD | Zentalis Pharmaceuticals Llc | 43 | |
| Sharon Klahre | Syndax Pharmaceuticals | N/A | |
| Kennett Sprogoe | Ascendis Pharma AS | 45 | |
| PharmD Rasbach | Zentalis Pharmaceuticals Llc | 44 | |
| Jonathan JD | Stoke Therapeutics | 34 | |
| Adrian MD | Zentalis Pharmaceuticals Llc | N/A | |
Management Performance
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.19 |
2Seventy Bio Leadership Team
Elected by the shareholders, the 2Seventy Bio's board of directors comprises two types of representatives: 2Seventy Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of 2Seventy. The board's role is to monitor 2Seventy Bio's management team and ensure that shareholders' interests are well served. 2Seventy Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, 2Seventy Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Susan AbuAbsi, Chief Officer | ||
| Teresa JD, General VP | ||
| Nick Leschly, President Director | ||
| DPHIL Phil, Chief Officer | ||
| Anna TruppelHartmann, Chief Officer | ||
| Victoria Eatwell, Chief Officer | ||
| Steven Shamah, Head Research | ||
| MS MD, Head Devel | ||
| Jessica Snow, Senior Operations | ||
| Anna MD, Chief Officer | ||
| Nicola Heffron, Chief Officer | ||
| William III, Chief Officer | ||
| Jenn Snyder, Senior Affairs | ||
| MBA III, Principal Officer | ||
| Steven MD, Chief Officer | ||
| Kathleen Wilkinson, Head Culture | ||
| Kerri Jensen, Head Culture | ||
| Vicki Eatwell, Chief Officer | ||
| Michael Certo, VP Editing |
2Seventy Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is 2Seventy Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (2.07) % | ||||
| Operating Margin | (0.99) % | ||||
| Current Valuation | 241.28 M | ||||
| Shares Outstanding | 51.59 M | ||||
| Shares Owned By Insiders | 4.05 % | ||||
| Shares Owned By Institutions | 90.88 % | ||||
| Number Of Shares Shorted | 5.41 M | ||||
| Price To Book | 0.82 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for 2Seventy Stock Analysis
When running 2Seventy Bio's price analysis, check to measure 2Seventy Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 2Seventy Bio is operating at the current time. Most of 2Seventy Bio's value examination focuses on studying past and present price action to predict the probability of 2Seventy Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 2Seventy Bio's price. Additionally, you may evaluate how the addition of 2Seventy Bio to your portfolios can decrease your overall portfolio volatility.